These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 3488858)

  • 1. Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).
    Schifferli JA; Steiger G; Paccaud JP
    Clin Exp Immunol; 1986 May; 64(2):407-14. PubMed ID: 3488858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of human C3a, C4a, and C5a anaphylatoxins by protein A of Staphylococcus aureus and immobilized protein A reagents used in serotherapy of cancer.
    Langone JJ; Das C; Bennett D; Terman DS
    J Immunol; 1984 Aug; 133(2):1057-63. PubMed ID: 6610702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
    Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
    Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization.
    Schifferli JA; Steiger G; Hauptmann G; Spaeth PJ; Sjöholm AG
    J Clin Invest; 1985 Dec; 76(6):2127-33. PubMed ID: 2934406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaphylatoxin levels in human aqueous humor.
    Mondino BJ; Sumner H
    Invest Ophthalmol Vis Sci; 1986 Aug; 27(8):1288-92. PubMed ID: 3488296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relative inefficiency of terminal complement activation.
    Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
    J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Difference in the biological properties of the two forms of the fourth component of human complement (C4).
    Schifferli JA; Steiger G; Paccaud JP; Sjöholm AG; Hauptmann G
    Clin Exp Immunol; 1986 Feb; 63(2):473-7. PubMed ID: 3486068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation in patients with primary antiphospholipid syndrome.
    Oku K; Atsumi T; Bohgaki M; Amengual O; Kataoka H; Horita T; Yasuda S; Koike T
    Ann Rheum Dis; 2009 Jun; 68(6):1030-5. PubMed ID: 18625630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaphylatoxin levels in human vitreous humor.
    Mondino BJ; Sidikaro Y; Sumner H
    Invest Ophthalmol Vis Sci; 1988 Jul; 29(7):1195-8. PubMed ID: 3262096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a.
    Reed SL; Ember JA; Herdman DS; DiScipio RG; Hugli TE; Gigli I
    J Immunol; 1995 Jul; 155(1):266-74. PubMed ID: 7602103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyacrylonitrile complement activation attenuated by simultaneous ultrafiltration and adsorption.
    Röckel A; Hertel J; Perschel WT; Walb D; Fiegel P; Panitz N; Abdelhamid S
    Nephrol Dial Transplant; 1987; 2(4):251-3. PubMed ID: 3118267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C5a: a mediator of chemotaxis and cellular release reactions.
    Gerard C; Hugli TE
    Kroc Found Ser; 1981; 14():147-60. PubMed ID: 6975805
    [No Abstract]   [Full Text] [Related]  

  • 14. Complement and dengue haemorrhagic fever/shock syndrome.
    Malasit P
    Southeast Asian J Trop Med Public Health; 1987 Sep; 18(3):316-20. PubMed ID: 3501613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement activation and anaphylatoxin (C3a and C5a) formation in preeclampsia and by amniotic fluid.
    Haeger M; Bengtson A; Karlsson K; Heideman M
    Obstet Gynecol; 1989 Apr; 73(4):551-6. PubMed ID: 2784554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation of three separate anaphylatoxins from complement-activated human serum.
    Hugli TE; Gerard C; Kawahara M; Scheetz ME; Barton R; Briggs S; Koppel G; Russell S
    Mol Cell Biochem; 1981 Dec; 41():59-66. PubMed ID: 6977086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma lactoferrin reflects granulocyte activation via complement in burn patients.
    Wolach B; Coates TD; Hugli TE; Baehner RL; Boxer LA
    J Lab Clin Med; 1984 Feb; 103(2):284-93. PubMed ID: 6607301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purification and functional assessment of C3a, C4a and C5a of the common carp (Cyprinus carpio) complement.
    Kato Y; Nakao M; Shimizu M; Wariishi H; Yano T
    Dev Comp Immunol; 2004 Jul; 28(9):901-10. PubMed ID: 15183031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of immune complexes by the classical pathway.
    Whaley K; Ahmed AE
    Behring Inst Mitt; 1989 Jul; (84):111-20. PubMed ID: 2529842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The activation of C3 and C4 in human serum by immune complexes containing mouse monoclonal antibodies of different isotype and affinity: effects on solubilisation.
    Stewart WW; Johnson A; Steward MW; Whaley K; Kerr MA
    Mol Immunol; 1988 Dec; 25(12):1355-61. PubMed ID: 3266294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.